MPI-based bioinformatic analysis and co-inhibitory therapy with mannose for oral squamous cell carcinoma

Yufei Yao1, Wei Liu1, Jia Li1

  • 1State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, No. 14 Renmin South Road, Chengdu, 610041, Sichuan, People's Republic of China.

Insights

Mannose inhibits oral squamous cell carcinoma (OSCC) by targeting the mannose phosphate isomerase gene (MPI). Lower MPI expression correlates with better survival, suggesting MPI as a therapeutic target in head and neck squamous cell carcinoma (HNSC).

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • Mannose induces tumor cell apoptosis and inhibits glucose metabolism.
  • Tumor drug sensitivity is inversely related to mannose phosphate isomerase (MPI) gene expression.

Purpose of the Study:

  • To investigate the association between MPI expression and immune infiltration, genetic, and clinical features in head and neck squamous cell carcinoma (HNSC).
  • To explore the combined therapeutic effects of mannose with genotoxicity, immune responses, and microbiome modulation in oral squamous cell carcinoma (OSCC).

Main Methods:

  • Bioinformatic analysis of MPI gene expression in HNSC.
  • In vitro and in vivo experiments on OSCC cell lines and mouse models.
  • Assessment of immune cell infiltration, cytokine expression, and microbiome changes.

Main Results:

  • Lower MPI expression in HNSC patients correlated with higher survival rates.
  • MPI expression was linked to DNA damage response genes; ATM inhibitor showed synergistic effects with mannose.
  • Mannose modulated immune cell populations, decreasing CD8+ T cells and increasing myeloid-derived suppressor cells (MDSCs) in antibiotic-treated mice.

Conclusions:

  • The MPI gene is significantly correlated with immune infiltration and clinical characteristics in HNSC.
  • Combining mannose with ATM inhibitors, immune modulators (CD8+ T cells, MDSCs), and microbiome interventions shows potential for co-inhibitory therapy in OSCC.